Table 3:
Multivariable Logistic Regression Model of Odds of Severe Complication
| Odds Ratio (95% CI) n = 415 |
p-value | |
|---|---|---|
|
| ||
| Neoadjuvant Therapy | ||
|
| ||
| CRT | REF | |
| SC-TNT | 0.42 (0.04 – 4.48) | 0.48 |
|
| ||
| Age | ||
|
| ||
| 18–49 | REF | |
| 50–65 | 0.49 (0.20 – 1.19) | 0.12 |
| >65 | 0.48 (0.17 – 1.40) | 0.18 |
|
| ||
| Gender | ||
|
| ||
| Female | REF | |
| Male | 1.44 (0.69 – 2.99) | 0.33 |
|
| ||
| Comorbidities | ||
|
| ||
| BMI≥30 | 0.90 (0.44 – 1.87) | 0.78 |
| ASA>2 | 3.02 (1.42 – 6.45) | <0.01* |
|
| ||
| Insurance Coverage | ||
|
| ||
| Private | REF | |
| Government | 2.07 (0.93 – 4.59) | 0.07 |
| Uninsured | 1.12 (0.11 – 11.2) | 0.92 |
|
| ||
| Clinical Nodal Stage | ||
|
| ||
| Node Negative | REF | |
| Node Positive | 1.09 (0.52 – 2.29) | 0.81 |
|
| ||
| Duration of Neoadjuvant Chemotherapy | ||
|
| ||
| 0 months | REF | |
| 1 – 3 months | 2.82 (0.25 – 31.30) | 0.40 |
| 4 – 6 months | 1.96 (0.13 – 30.25) | 0.63 |
|
| ||
| Approach | ||
|
| ||
| Minimally Invasive | REF | |
| Open | 1.02 (0.49 – 2.09) | 0.96 |
|
| ||
| Tumor height (cm) | ||
|
| ||
| 11 – 15 | REF | |
| 6 – 10 | 0.70 (0.22 – 2.24) | 0.55 |
| 0 – 5 | 0.54 (0.16 – 1.84) | 0.32 |
|
| ||
| Procedure | ||
|
| ||
| LAR | REF | |
| APR | 3.77 (1.49 – 9.52) | <0.01* |
| MOR | 7.10 (2.12 – 23.76) | 0.001* |
*
Legend: denotes significance; LAR=Low Anterior Resection; APR=Abdominoperineal Resection; MOR=Multiorgan Resection